Targeting refractory prostate cancer: A novel radiopharmaceutical hits the bullseye
by Osaka UniversityTargeted alpha therapy using an astatine-labeled PSMA ligand ([At-211]PSMA5). Credit: Tadashi Watabe (Osaka University)As the saying goes, when all you have is a hammer, everyt
Updated on: February 23,2024
13
Targeting refractory prostate cancer: A novel radiopharmaceutical hits the bullseye
by Osaka UniversityTargeted alpha therapy using an astatine-labeled PSMA ligand ([At-211]PSMA5). Credit: Tadashi Watabe (Osaka University)As the saying goes, when all you have is a hammer, everyt
Updated on:February 23,2024
13
